Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | F7 | P08709 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | F3 | P13726 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | VHL | P40337 | 1/20 | 0.44 |
| ▸ | ELOC | Q15369 | 1/20 | 0.44 |
| ▸ | ELOB | Q15370 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29721553 | 1.00 | MEN1 (0.47) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL6977492 | 0.89 | MEN1 (0.58) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL30051842 | 0.86 | GAA (0.44) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL3531650 | 0.86 | GAA (0.44) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL26405759 | 0.79 | F7 (0.40) | MAPTKDM4EALDH1A1SMN1; SMN2F7 | |
| SCHEMBL6339024 | 0.79 | MEN1 (0.47) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL14255904 | 0.79 | ALDH1A1 (0.47) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL19649488 | 0.79 | ALDH1A1 (0.47) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL3534887 | 0.76 | PARP10 (0.51) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL6256563 | 0.75 | MEN1 (0.54) | MEN1KMT2AMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117756717-A | Tolvaptan intermediate and preparation method of tollvaptan | 广州市桐晖药业有限公司 | 2024-03-26 | — | — | CN | claimed |
| US-9024015-B2 | Process for preparing tolvaptan intermediates | HETERO RESEARCH FOUNDATION (IN) | 2015-05-05 | — | — | US | claimed |
| EP-2624693-A1 | PROCESS FOR PREPARING TOLVAPTAN INTERMEDIATES | Hetero Research Foundation (IN) | 2013-08-14 | — | — | EP | claimed |
| US-20130190490-A1 | PROCESS FOR PREPARING TOLVAPTAN INTERMEDIATES | HETERO RESEARCH FOUNDATION (IN) | 2013-07-25 | — | — | US | claimed |
| WO-2012046244-A1 | PROCESS FOR PREPARING TOLVAPTAN INTERMEDIATES | HETERO RESEARCH FOUNDATION (IN) | 2012-04-12 | — | — | WO | claimed |
| CN-119604507-A | Benzazepine ring compound salt form, crystal form and application thereof | 上海济煜医药科技有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-117756717-A | Tolvaptan intermediate and preparation method of tollvaptan | 广州市桐晖药业有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-114736119-B | One-step preparation method of ethyl 4-bromobutyrate | 迈奇化学股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-4253367-A1 | NOVEL BENZAZEPINE SPIRO DERIVATIVE | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2023-10-04 | — | — | EP | disclosed |
| EP-4253367-A1 | NOVEL BENZAZEPINE SPIRO DERIVATIVE | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2023-10-04 | — | — | EP | disclosed |
| CN-219744775-U | Continuous production device of ethyl 4-bromobutyrate | 迈奇化学股份有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-219424407-U | Continuous reactor of ethyl 4-bromobutyrate | 迈奇化学股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-2251319-A2 | Process for preparing derivatives of benzoic acid | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-20090306369-A1 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-1919874-A2 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | Otsuka Pharmaceutical Company, Limited (JP) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007026971-A2 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-5677299-A | VASOPRESSIN OR OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1997-10-14 | — | — | US | disclosed |
| US-5498609-A | Benzoazepinyl compounds as oxytocin and vasopressin antagonists | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1996-03-12 | — | — | US | disclosed |
| EP-0612319-A1 | BENZOHETEROCYCLIC COMPOUNDS AS OXYTOCIN AND VASOPRESSIN ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-08-31 | — | — | EP | disclosed |
| WO-1994004525-A1 | BENZOHETEROCYCLIC COMPOUNDS AS OXYTOCIN AND VASOPRESSIN ANTAGONISTS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306369-A1 | PROCESS FOR PREPARING BENZAZEPINE COMPOUNDS OR SALTS THEREOF | AVPR2, AVPR1B, AVPR1A | MEN1 224/4885KMT2A 1587/4885MAPT 3415/4885 |
| US-20130190490-A1 | PROCESS FOR PREPARING TOLVAPTAN INTERMEDIATES | HTR5A, TPH1, HTR4 | MEN1 1523/4885KMT2A 967/4885MAPT 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.